[go: up one dir, main page]

CZ20004592A3 - Benzo(b)thiepin-1,1-dioxidové deriváty, způsob jejich přípravy, léčiva obsahující tyto sloučeniny a jejich použití - Google Patents

Benzo(b)thiepin-1,1-dioxidové deriváty, způsob jejich přípravy, léčiva obsahující tyto sloučeniny a jejich použití

Info

Publication number
CZ20004592A3
CZ20004592A3 CZ20004592A CZ20004592A CZ20004592A3 CZ 20004592 A3 CZ20004592 A3 CZ 20004592A3 CZ 20004592 A CZ20004592 A CZ 20004592A CZ 20004592 A CZ20004592 A CZ 20004592A CZ 20004592 A3 CZ20004592 A3 CZ 20004592A3
Authority
CZ
Czechia
Prior art keywords
thiepine
benzo
compounds
preparation
medicaments containing
Prior art date
Application number
CZ20004592A
Other languages
English (en)
Other versions
CZ297989B6 (cs
Inventor
Wendelin Frick
Alfons Enhsen
Heiner Glombik
Hubert Heuer
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of CZ20004592A3 publication Critical patent/CZ20004592A3/cs
Publication of CZ297989B6 publication Critical patent/CZ297989B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CZ20004592A 1998-06-10 1999-05-28 Benzo(b)thiepin-1,1-dioxidové deriváty, zpusob jejich prípravy, léciva obsahující tyto deriváty a pouzití techto derivátu CZ297989B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19825804A DE19825804C2 (de) 1998-06-10 1998-06-10 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (2)

Publication Number Publication Date
CZ20004592A3 true CZ20004592A3 (cs) 2001-04-11
CZ297989B6 CZ297989B6 (cs) 2007-05-16

Family

ID=7870440

Family Applications (2)

Application Number Title Priority Date Filing Date
CZ20004592A CZ297989B6 (cs) 1998-06-10 1999-05-28 Benzo(b)thiepin-1,1-dioxidové deriváty, zpusob jejich prípravy, léciva obsahující tyto deriváty a pouzití techto derivátu
CZ20004591A CZ297925B6 (cs) 1998-06-10 1999-05-29 Deriváty benzothiepin-1,1-dioxidu, zpusob jejich prípravy a léciva s jejich obsahem

Family Applications After (1)

Application Number Title Priority Date Filing Date
CZ20004591A CZ297925B6 (cs) 1998-06-10 1999-05-29 Deriváty benzothiepin-1,1-dioxidu, zpusob jejich prípravy a léciva s jejich obsahem

Country Status (25)

Country Link
US (1) US6387944B1 (cs)
EP (2) EP1086092B1 (cs)
JP (2) JP4374426B2 (cs)
KR (2) KR100681721B1 (cs)
CN (2) CN1127497C (cs)
AR (2) AR018634A1 (cs)
AT (2) ATE227715T1 (cs)
AU (2) AU753275B2 (cs)
BR (2) BR9912188B1 (cs)
CA (2) CA2334775C (cs)
CZ (2) CZ297989B6 (cs)
DE (3) DE19825804C2 (cs)
DK (2) DK1086092T3 (cs)
ES (2) ES2182535T3 (cs)
HU (2) HU229761B1 (cs)
ID (2) ID28695A (cs)
IL (1) IL140078A (cs)
NO (1) NO327075B1 (cs)
NZ (1) NZ508681A (cs)
PL (2) PL196074B1 (cs)
PT (2) PT1086092E (cs)
RU (2) RU2215001C2 (cs)
TR (2) TR200003634T2 (cs)
WO (2) WO1999064410A1 (cs)
ZA (2) ZA200007061B (cs)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE69908643T2 (de) 1998-12-23 2004-05-13 G.D. Searle Llc, Chicago Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
DE10064402A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Gmbh Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
DE50111751D1 (de) * 2000-12-21 2007-02-08 Sanofi Aventis Deutschland Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
WO2003018024A1 (de) * 2001-08-22 2003-03-06 Aventis Pharma Deutschland Gmbh Kombinationspräparate von 1,4- benzothiepin-1,1-dioxidderivaten mit weiteren wirkstoffen und deren verwendung
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
MY131995A (en) 2001-09-08 2007-09-28 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
JP2005521653A (ja) 2002-01-17 2005-07-21 ファルマシア コーポレイション 先端ナトリウム同時依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取込みの阻害剤としての新規アルキル／アリールヒドロキシまたはケトチエピン化合物
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
US20040138145A1 (en) * 2002-12-12 2004-07-15 Aventis Pharma S.A. Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
DE102006053636B4 (de) * 2006-11-14 2008-09-18 Sanofi-Aventis Deutschland Gmbh Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung
DE102006053635B4 (de) * 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20100221513A1 (en) * 2008-09-05 2010-09-02 Wisconsin Alumni Research Foundation Self sintering transparent nanoporous thin-films for use in self-cleaning, anti-fogging, anti-corrosion, anti-erosion electronic and optical applications
EP4137137A1 (en) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CA2815749C (en) 2010-11-04 2019-12-03 Albireo Ab Ibat inhibitors for the treatment of liver diseases
SG190433A1 (en) 2010-11-08 2013-06-28 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
EP2770990A4 (en) 2011-10-28 2015-03-11 Lumena Pharmaceuticals Inc Gallic acid refluxing agent for the treatment of hypertension and chronic liver disease
PT2771003T (pt) 2011-10-28 2017-07-26 Lumena Pharmaceuticals Llc Inibidores da reciclagem de ácidos biliares para tratamento de doenças hepáticas colestáticas pediátricas
AU2014228850A1 (en) 2013-03-15 2015-10-29 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
MX2015013196A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett.
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
JP6751020B2 (ja) 2014-06-25 2020-09-02 Ｅａファーマ株式会社 固形製剤及びその着色防止又は着色低減方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
EP3413878B1 (en) 2016-02-09 2021-04-14 Albireo AB Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
JP6954926B2 (ja) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
WO2019032027A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
TW202015699A (zh) 2018-06-05 2020-05-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2019245448A1 (en) 2018-06-20 2019-12-26 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN118834175A (zh) 2019-02-06 2024-10-25 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
MX2021008981A (es) 2019-02-06 2021-09-08 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del acido biliar.
WO2020167964A1 (en) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
AR120679A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
BR112022010505A2 (pt) 2019-12-04 2022-09-06 Albireo Ab Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CN114761018B (zh) 2019-12-04 2025-12-02 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
AR120676A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
TWI877263B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
WO2021110884A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CN114761080B (zh) 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023549226A (ja) 2020-11-12 2023-11-22 アルビレオ エービー 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット
WO2022117778A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CN119343140A (zh) 2022-06-09 2025-01-21 阿尔比里奥公司 治疗肝炎
AU2023304672A1 (en) 2022-07-05 2025-01-02 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US20240207286A1 (en) 2022-12-09 2024-06-27 Albireo Ab Asbt inhibitors in the treatment of renal diseases
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
CN1084741C (zh) * 1994-09-13 2002-05-15 孟山都公司 具有回肠胆汁酸转运和牛磺胆酸盐摄入抑制剂作用的新的苯并硫杂䓬
CN1515567A (zh) * 1996-03-11 2004-07-28 G.D.ɪ����˾ 具有作为回肠胆汁酸转运和牛磺胆酸盐吸收抑制剂活性的新的苯并噻庚因
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
US6096780A (en) * 1998-08-20 2000-08-01 Takeda Chemical Industries, Ltd. Quaternary ammonium salts and their use

Also Published As

Publication number Publication date
CA2334775A1 (en) 1999-12-16
HUP0102554A3 (en) 2002-12-28
ES2182535T3 (es) 2003-03-01
WO1999064409A3 (de) 2000-03-02
US6387944B1 (en) 2002-05-14
PL196074B1 (pl) 2007-12-31
CA2334773C (en) 2009-05-26
HK1039490A1 (en) 2002-04-26
ATE259372T1 (de) 2004-02-15
JP2002517491A (ja) 2002-06-18
CZ20004591A3 (cs) 2001-04-11
IL140078A0 (en) 2002-02-10
KR100562184B1 (ko) 2006-03-20
PL345901A1 (en) 2002-01-14
AU4503199A (en) 1999-12-30
PT1086113E (pt) 2004-06-30
JP2002517490A (ja) 2002-06-18
HK1036799A1 (en) 2002-01-18
CN1305487A (zh) 2001-07-25
EP1086092B1 (de) 2002-11-13
EP1086113A2 (de) 2001-03-28
CZ297925B6 (cs) 2007-05-02
PL344827A1 (en) 2001-11-19
JP4374426B2 (ja) 2009-12-02
BR9911123A (pt) 2006-01-03
DE19825804C2 (de) 2000-08-24
WO1999064410A1 (de) 1999-12-16
KR100681721B1 (ko) 2007-02-15
IL140078A (en) 2004-08-31
ATE227715T1 (de) 2002-11-15
RU2220141C2 (ru) 2003-12-27
DE59908522D1 (de) 2004-03-18
DE19825804A1 (de) 1999-12-16
JP3374129B2 (ja) 2003-02-04
ZA200007061B (en) 2001-07-18
ID26876A (id) 2001-02-15
ES2215387T3 (es) 2004-10-01
HUP0102256A3 (en) 2002-04-29
AR018633A1 (es) 2001-11-28
AU4501999A (en) 1999-12-30
CN1305469A (zh) 2001-07-25
TR200003634T2 (tr) 2001-06-21
NO327075B1 (no) 2009-04-20
CZ297989B6 (cs) 2007-05-16
AU753275B2 (en) 2002-10-10
DK1086113T3 (da) 2004-05-24
EP1086092A1 (de) 2001-03-28
NO20006251D0 (no) 2000-12-08
DK1086092T3 (da) 2003-03-10
CA2334775C (en) 2009-10-13
HUP0102554A1 (hu) 2001-10-28
KR20010052701A (ko) 2001-06-25
HU229761B1 (hu) 2014-06-30
RU2215001C2 (ru) 2003-10-27
EP1086113B1 (de) 2004-02-11
CA2334773A1 (en) 1999-12-16
DE59903411D1 (de) 2002-12-19
ID28695A (id) 2001-06-28
HU228570B1 (en) 2013-04-29
PL196057B1 (pl) 2007-11-30
PT1086092E (pt) 2003-03-31
BR9911123B1 (pt) 2010-12-14
BR9912188B1 (pt) 2010-12-14
CN1152039C (zh) 2004-06-02
AU752633B2 (en) 2002-09-26
HUP0102256A1 (hu) 2001-12-28
NO20006251L (no) 2001-02-07
NZ508681A (en) 2002-06-28
TR200003632T2 (tr) 2001-04-20
AR018634A1 (es) 2001-11-28
BR9912188A (pt) 2001-04-10
CN1127497C (zh) 2003-11-12
KR20010052682A (ko) 2001-06-25
ZA200007060B (en) 2001-07-18
WO1999064409A2 (de) 1999-12-16

Similar Documents

Publication Publication Date Title
CZ20004592A3 (cs) Benzo(b)thiepin-1,1-dioxidové deriváty, způsob jejich přípravy, léčiva obsahující tyto sloučeniny a jejich použití
IL145647A0 (en) 1,4-benzothiazepine -1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
DE69907964D1 (de) 1,2-annelierte chinolinderivate
ATE340177T1 (de) 12,13-modifizierte epothilon-derivate
MA24564A1 (fr) Derives substitues en c-4 ''de 9-desoxo-9a-aza-9a-homoerythromycine a
NZ297342A (en) Thiadiazolidin-3-one 1,1-dioxides; medicaments
DE69612852D1 (de) BENZO[g]CHINOLINDERIVATE
FI962751A7 (fi) Uusia hydroksyyliryhmän sisältäviä 1,3-dialkyyliureajohdannaisia
DK0966477T3 (da) 3'-N-oxid, 3'-N-dimethylamin, 9-oxim-erythromycin A-derivater
NZ240378A (en) Substituted thiazolidinedione derivatives; pharmaceutical compositions,
IL154408A0 (en) 10-ARYL-11-H BENZO [b] FLUORENE DERIVATIVES AND ANALOGS FOR MEDICINAL USE
PL310439A1 (en) Application of derivatives of 2-h-1,2,4-benzothiazin-3/4h/-one 1,1-dioxide as noncompetitive antagonists of nmda receptor
HUP9800964A3 (en) O and s containing 6 membered benzo fused heterocyclic compounds, a process for their preparation and pharmaceuticals containing them
FI973644A0 (fi) Uusi menetelmä 2,3-dihydrobentsofuranolijohdannaisten valmistamiseksi
NZ300041A (en) 2-(2,3,5,6-tetrafluoropyridin-4-yl)-1,2,5-thiazolidin-3-one 1,1-dioxide derivatives
AU4137000A (en) Benzo((b)) thiophene sulfonamide-1, 1-dioxide derivatives and their use as antineoplastic agents
MD266B1 (ro) Procedeu de obtinere a derivatilor 5-haloidtienoizotiazol-3(2h)-on-1,1-dioxizilor
NO996392L (no) Angiogenese-inhiberende 5-substituerte-1,2,4-tiadiazolyl- derivater
PL326338A1 (en) New furane derivatives of 1,3-dioxane
ITMI940683A1 (it) Derivati di benzo (b) decalin-5, 10-dioni-2, 3, 4-alfa, 10-alfa-deidro ad attivita' antitumorale
ATE119892T1 (de) Benzothiazin-1,1-dioxid-derivate.
FR2812546B1 (fr) Derives d'heterocycles a 5 chainons, leur preparation et leur application a titre de medicaments
HU9903043D0 (en) New benzo[d]isoxazole derivatives, process for their preparation and pharmaceutical compositions containing them
NZ232955A (en) Composition comprising a b-blocker and 5-(5-methyl-3-oxo-4,5-dihydro-2h-6-pyridazinyl)-benzimidazole derivatives; preparation thereof
HUP9902590A3 (en) 3,4-dihydro isoquinolinium derivatives, pharmaceutical compositions containing them and process for producing them

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20150528